In Silico Studies to Support Vaccine Development
- PMID: 36839975
- PMCID: PMC9963741
- DOI: 10.3390/pharmaceutics15020654
In Silico Studies to Support Vaccine Development
Abstract
The progress that has been made in computer science positioned in silico studies as an important and well-recognized methodology in the drug discovery and development process. It has numerous advantages in terms of costs and also plays a huge impact on the way the research is conducted since it can limit the use of animal models leading to more sustainable research. Currently, human trials are already being partly replaced by in silico trials. EMA and FDA are both endorsing these studies and have been providing webinars and guidance to support them. For instance, PBPK modeling studies are being used to gather data on drug interactions with other drugs and are also being used to support clinical and regulatory requirements for the pediatric population, pregnant women, and personalized medicine. This trend evokes the need to understand the role of in silico studies in vaccines, considering the importance that these products achieved during the pandemic and their promising hope in oncology. Vaccines are safer than other current oncology treatments. There is a huge variety of strategies for developing a cancer vaccine, and some of the points that should be considered when designing the vaccine technology are the following: delivery platforms (peptides, lipid-based carriers, polymers, dendritic cells, viral vectors, etc.), adjuvants (to boost and promote inflammation at the delivery site, facilitating immune cell recruitment and activation), choice of the targeted antigen, the timing of vaccination, the manipulation of the tumor environment, and the combination with other treatments that might cause additive or even synergistic anti-tumor effects. These and many other points should be put together to outline the best vaccine design. The aim of this article is to perform a review and comprehensive analysis of the role of in silico studies to support the development of and design of vaccines in the field of oncology and infectious diseases. The authors intend to perform a literature review of all the studies that have been conducted so far in preparing in silico models and methods to support the development of vaccines. From this point, it was possible to conclude that there are few in silico studies on vaccines. Despite this, an overview of how the existing work could support the design of vaccines is described.
Keywords: PBPK; PopPK; computational; in silico; population pharmacokinetics; vaccines.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1. Arch Razi Inst. 2021. PMID: 33818952 Free PMC article.
-
The First Physiologically Based Pharmacokinetic (PBPK) Model for an Oral Vaccine Using Alpha-Tocopherol as an Adjuvant.Pharmaceutics. 2023 Sep 13;15(9):2313. doi: 10.3390/pharmaceutics15092313. Pharmaceutics. 2023. PMID: 37765281 Free PMC article.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Eur J Pharm Biopharm. 2015. PMID: 25813885 Review.
Cited by
-
T Cell Peptide Prediction, Immune Response, and Host-Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 Subjects.Biomolecules. 2024 Sep 26;14(10):1217. doi: 10.3390/biom14101217. Biomolecules. 2024. PMID: 39456150 Free PMC article.
-
In Silico Design and Characterization of a Multiepitope Vaccine Candidate Against Brucella canis Using a Reverse Vaccinology Approach.J Immunol Res. 2025 Apr 15;2025:6348238. doi: 10.1155/jimr/6348238. eCollection 2025. J Immunol Res. 2025. PMID: 40265107 Free PMC article.
-
Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics.Vaccines (Basel). 2024 Jul 16;12(7):782. doi: 10.3390/vaccines12070782. Vaccines (Basel). 2024. PMID: 39066420 Free PMC article. Review.
-
Cutting-Edge Advances in Anticancer Therapies: Insights from the Third Edition of the Special Issue "Novel Anticancer Strategies".Pharmaceutics. 2025 Jan 3;17(1):54. doi: 10.3390/pharmaceutics17010054. Pharmaceutics. 2025. PMID: 39861702 Free PMC article.
-
In vitro identification of neutralizing epitopes of Rhipicephalus microplus serpin 17 (RmS-17).Vaccine. 2024 Aug 13;42(20):126161. doi: 10.1016/j.vaccine.2024.126161. Epub 2024 Jul 26. Vaccine. 2024. PMID: 39060200 Free PMC article.
References
-
- Bilusic P.J.D.M. Cancer Vaccines. Hematol. Oncol. Clin. N. Am. 2019;33:199–214. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials